GB Sciences Inc (GBLX)

[3DYOGI]

The GBLX Drug Discovery Program has 5 strategic advantages that allow the company to patent protect the GBLX Accelerated Drug Development Program to finish in 3-5 years instead of the 15-20 years required in the traditional pharmaceutical development program.

Certified Cannabis Extracts = Clinical Testing Materials
Phase IV Human Trials > Medical Cannabis Dispensaries
GBLX-PRO APP = Drug Discovery Engine
Accelerated Regulatory Strategy > Fast Track Approvals
GBLX Research Partners GBLX Drug Development Ecosystem
How the Accelerated Development Program Works

How do you get from phase I to phase IV human trials in less than 15 years and for less than $1 billion? Start with phase IV. Under state-regulated medical marijuana programs, GB Sciences can validate the effectiveness of its cannabis-based therapies in human phase IV clinical trials (1) that are coordinated through the GBLX-PRO smartphone app (2). The GBLX-PRO app coordinates strain profile information with symptom relief as a part of the GBLX Drug Discovery Program. The GBLX Accelerated Regulatory Strategy leverages established cannabis safety profiles as well as fast-track approvals or orphan drug designations to reduce clinical trial times and expenses (3). GBLX is also able to earn revenue from sales of the certified raw materials through dispensaries sales during the drug discovery process (4).